is a biopharmaceutical company engaged in the discovery and development of a novel class of therapeutic proteins based on Soluble receptors (“traps”) for a range of serious human diseases, including cardiovascular diseases, ophthalmology and cancer. Today, the Company has seven molecules in the pipeline
We target diabetic retinopathy (DR) and age-related macular degeneration (ARM). DR, or diabetic eye disease, is a leading cause of blindness. It affects up to 80 percent of people who have had diabetes for 20 years or more. DR accounts for 12% of all new cases of blindness. ARM is a relatively common eye disease and is the leading cause of severe vision loss in people 65 years or older. In 2015 it affected 6.2 million people globally
Cardiovascular disease is a global public health problem contributing to 30% of global mortality and 10% of the global disease burden. In 2005, from a total of 58 million deaths worldwide, 17 million were due to cardiovascular disease and, among them, 7.6 million were due to coronary heart disease
Stroke is a situation when blood flow to the brain results in cell death, causing part of the brain not functioning properly. In 2015, stroke was the second most frequent cause of death after coronary artery disease, accounting for 6.3 million deaths (11% of the total). About 11 million deaths resulted stroke. About half of people who have had a stroke live less than one year
Colorectal cancer, also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum (parts of the large intestine). A cancer is the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Globally, colorectal cancer is the third most common type of cancer, making up about 10% of all cases. In 2012, there were 1.4 million new cases and 694,000 deaths from the disease
Critical limb ischemia, also referred to as limb threat, is an advanced stage of peripheral artery disease. It is defined as a triad of ischemic rest pain, arterial insufficiency ulcers, and gangrene. More than 100 million people are suffering from the disease. It has a negative prognosis within a year after the initial diagnosis, with 1-year amputation rates of approximately 12% and mortality of 50% at 5 years and 70% at 10 years
Rheumatoid arthritis is a long-term autoimmune disorder that primarily affects joints. It typically results in warm, swollen, and painful joints. Pain and stiffness often worsen following rest. It affects about 24.5 million people as of 2015. In 2013, it resulted in 38,000 deaths up from 28,000 deaths in 1990
Soluble receptors ("trap") is intended for the treatment of cancer, cardiovascular and eye diseases.
Technology enables development of highly specific and powerful growth factor binders / blockers in a much faster and cost-effective way than monoclonal antibodies. No immunization, no screening and no humanization steps
Traps can be easily modified to optimize their binding affinity, specificity and molecular size for the particular purposes by means of bioinformatic analysis and genetic engineering
Similar approaches have been validated, but have not been extensively used by other pharmaceutical companies to date
Multiple indications for a single target / drug candidate as well as multiple drug candidates in portfolio will increase chances of the successful clinical drugs development
Production of non-clinical grade analytical and diagnostic products as well as custom-made molecules will provide rapid and stable financial income
Unlike antibodies, traps block receptor-ligand interaction when exact sites or mode of action (of the receptor-ligand complex) is unknown due to the steric hindrance
GR & PR Director
20+ years of managerial and scientific roles in Russian, European and North American Universities and organizations (SPbU, Helsinki U, U of Oslo, WWF of Sweden, Baltic Fond for Nature, NORDECO Denmark, Centre “Sirius”, and others). Has Awards by the President of Russia. PHD, Associate professor of SPbU. Author of more than 80 scientific articles and monographs
Founder, Chief Scientific Officer
Five-year experience of scientific research in the US academic institutes. 9 years of research in the US pharmaceutical industry. Co-author of biopharmaceutical blockbuster EYLEA® (aflibercept), the 7th best selling drug in the world with 7.9 Billions of revenues in 2020. PHD
Director, Cardiovascular diseases
Associate Professor, Dept. of Embryology, Biological Faculty, St.-Petersburg State University. Head of the Laboratory of Molecular Cardiology, Federal Almazov Medical Research Centre Saint-Petersburg, RF. PHD. h = 9
CTO
Associate Professor of the Department of Cytology and Histology of St. Petersburg State University; Director of the Resource Center of the Center for Chemistry of the Science Park of St. Petersburg State University. Dep.Head of Embryology Lab in International Centre for Reproductive Medicine. PHD. h=7
CEO
20+ top managerial experience in largest FMCG companies (Pepsi, Mars, Carlsberg) and banks (Citibank, Sberbank CIB-Troyka, UBRD). Entrepreneur and investor
Директор департамента общественного здоровья и коммуникаций Минздрава
Руководитель лаборатории постгеномных исследований института молекулярной биологии им. Энгельгардта, лауреат премии Президента для молодых ученых
Академик РАН, директор института биомедицинской химии им. В.Н. Ореховича
Секретарь секции Биология РАН, декан биологического факультета МГУ
Директор департамента общественного здоровья и коммуникаций Минздрава
Руководитель лаборатории постгеномных исследований института молекулярной биологии им. Энгельгардта, лауреат премии Президента для молодых ученых
Академик РАН, директор института биомедицинской химии им. В.Н. Ореховича
Секретарь секции Биология РАН, декан биологического факультета МГУ
Директор департамента общественного здоровья и коммуникаций Минздрава
Руководитель лаборатории постгеномных исследований института молекулярной биологии им. Энгельгардта, лауреат премии Президента для молодых ученых
Академик РАН, директор института биомедицинской химии им. В.Н. Ореховича
Секретарь секции Биология РАН, декан биологического факультета МГУ
The Patent Power 2020 competition is organized by the Skolkovo Foundation together with Bayer with the support of the World Intellectual Property Organization, the Eurasian Patent Office and the Federal Institute of Industrial Property (FIPS). More than 100 companies took part in Patent Power 2020. 71 projects reached the semifinals. Palmira Biopharma took second place in the competition and became a Grant winner.
Read moreAfter a careful selection process our project became a finalist in the category @Project of the Future in the @Pharmaceutics and Medicine stream. There were 740 participants, and our team is proud to compete with many strong candidates
Read moreThe structure of Aflibercept (Eylea), a fusion protein, made using "trap" technology by Ivan Lobov and a team. This drug is the one among the most prominent pharmaceutical blockbusters with 8,3 Billion annual sales worldwide in 2017
Read moreIn the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered. Drug discovery is a complex process taking in average 6 years of specific research before the pre-clinical tasting. We are proud to claim that we have 6 molecules ready for pre-clinical and the one is already in pre-clinical stage...
Read moreThe global biopharmaceutical portfolio of today reflects increased therapeutic competition, a greater prevalence of large molecule drugs and expansion in the number of personalized or targeted products. This 2+ minute animation from Repligen Corp provides a simple explanation of the process for manufacturing a biopharmaceutical drug. It includes a description of "upstream" fermentation and "downstream" capture and purification of the biologic product, using monoclonal antibodies as an example
Read moreMonoclonal antibodies are a growing class of biological agents for the treatment of a variety of diseases. Scientists are now looking at ways to modify their structure, to optimize their function within the body. This includes conjugating small molecular inhibitors to antibodies, so that the combined molecule can deliver the active ingredient to a highly specific site within the body
Read moreWe've all been touched by the miracles of modern medicine. But few people understand how medicines are made, and the immense effort required to get them to market and into our hands: this two minutes video will illustrate the drug development process, which usually takes 12-15 years and costs $1,3-1,6 Billions
Read moreThe article reports that Dll4 expression is dynamically regulated by VEGF in the retinal vasculature, where it is most prominently expressed at the leading front of actively growing vessels. Deletion of a single Dll4 allele or pharmacologic inhibition of Dll4/Notch signaling by intraocular administration of either soluble Dll4-Fc or a blocking antibody against Dll4 all produced the same set of characteristic abnormalities in the developing retinal vasculature, most notably enhanced angiogenic sprouting and increased endothelial cell proliferation, resulting in the formation of a denser and more highly interconnected superficial capillary plexus. The data demonstrate that Dll4 promotes the timely formation of a well differentiated vascular network
Read moreA flagship eye treatment, Eylea (aflibercept), created by Ivan Lobov and a team, became one of the bestselling drug in the world, adding US $7.9 billion in total sales.
Read moreOver the past three decades, 45 monoclonal antibody (MAbs) and MAb-derivative products have been approved for therapeutic use in the United States. One class of antibody derivatives is growing in importance: Fc-fusion proteins
Read moreNovember, the 30th: We have received the "Big Check" of support from DPIR, the Innovative development agency of Moscow government
Read moreOctober, the 22nd: The ceremony of awarding the winners of the Novator of Moscow Mayor's Prize took place in the capital's mayor's office. Authors of 18 unique projects became laureates.
Read moreEnglish version (voice-over) of a presentation
Read moreA great news that our Biopharma project become a finalist of the 10th Dongsheng CUP International Entrepreneurship competition: participants were from 37 countries, including 6th strong representatives from Russia. For this year, Competition is included in the ‘9th China-Russia Engineering and Technology Forum’ , co-hosting by CAST (China Association for Science and Technology), Russian Union of Scientific and Engineering Associations, and Tianjin Municipal Government, attributed to be the highest annual event in STI between our two contries. Will keep you posted as a date of Finals is coming. The winners to be anounced on the 8th of December 2022 a day after the the final pitches.
Read moreВы можете помочь проекту и перевести любую сумму, используя реквизиты ниже: